Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$22.14 USD

22.14
502,558

-0.16 (-0.72%)

Updated Jun 7, 2024 04:00 PM ET

After-Market: $22.14 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 248)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Will Edwards' (EW) Growth in All Lines Drive Q1 Earnings?

by Zacks Equity Research

Edwards Lifesciences (EW) is expected to gain from strength in all the business segments and solid performance across all geographies.

    Can Steady Overall Growth Drive Abbott's (ABT) Q1 Earnings?

    by Zacks Equity Research

    Abbott (ABT) to see impressive year-over-year rise in revenues on strength in all business segments in Q1.

      What's in Store for GNC Holdings (GNC) This Earnings Season?

      by Zacks Equity Research

      GNC Holdings (GNC) likely to witness year-over-year decline in revenues owing to weakness in the U.S. & Canada and Manufacturing/Wholesale segments in Q1.

        Intercept Pharmaceuticals (ICPT) in Focus: Stock Moves 9.9% Higher

        by Zacks Equity Research

        Intercept Pharmaceuticals (ICPT) shares rose nearly 10% in the last trading session, amid huge volumes.

          Myriad Genetics' BRACAnalysis Test Platform Gets PMA in Japan

          by Zacks Equity Research

          Myriad Genetics (MYGN) leaves no stone unturned to boost uptake of BRACAnalysis test and strengthen the Molecular Diagnostics portfolio.

            Myriad Genetics (MYGN) Down 3% Since Earnings Report: Can It Rebound?

            by Zacks Equity Research

            Myriad Genetics (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Myriad Genetics Banks on Product Launches, Competition Rife

              by Zacks Equity Research

              Myriad Genetics (MYGN) focuses on strengthening the Molecular Diagnostics portfolio through product launches.

                Myriad Genetics' Positive Study Data May Expand Customer Base

                by Zacks Equity Research

                Myriad Genetics (MYGN) leaves no stone unturned to drive the uptake of myRisk Hereditary Cancer test and strengthen the Molecular Diagnostics portfolio.

                  Myriad Genetics (MYGN) Beats on Earnings & Revenues in Q2

                  by Zacks Equity Research

                  Myriad Genetics' (MYGN) year over year decline in revenue was in Q2 is disappointing. However, strong demand for GeneSight tests was encouraging.

                    What's in Store for GNC Holdings (GNC) This Earnings Season?

                    by Zacks Equity Research

                    GNC Holdings (GNC) likely to see decline in year-over-year revenues owing to weakness in U.S. & Canada segment in Q4.

                      Will Covance Drug Development Drive LabCorp (LH) Q4 Earnings?

                      by Zacks Equity Research

                      LabCorp (LH) is expected to gain from LabCorp Diagnostics and Covance Drug Development segments in Q4.

                        ResMed (RMD) Rides on Product Launches, Robust Global Growth

                        by Zacks Equity Research

                        ResMed's (RMD) product launches and strategies to gain traction in the sleep-disordered breathing market. This upside is further likely to drive the stock in the future.

                          Quest Diagnostics to Buy MedXM, Boost Home Health Services

                          by Zacks Equity Research

                          Quest Diagnostics (DGX) actively pursues mergers and acquisitions to strengthen hold in the high-potential global home healthcare market.

                            FDA Nod for QIAGEN's JAK2 Test Boosts Molecular Diagnostic

                            by Zacks Equity Research

                            QIAGEN (QGEN) strives to enhance Molecular Diagnostic segment, which was the highest revenue grosser in the last reported quarter.

                              Can Molecular Diagnostics Drive Myriad's (MYGN) Q2 Earnings?

                              by Zacks Equity Research

                              Myriad (MYGN) positioned to deliver solid Q2 results on the diversified Molecular Diagnostics portfolio with products like GeneSight and EndoPredict tests.

                                Is AmerisourceBergen (ABC) Poised for a Beat in Q1 Earnings?

                                by Zacks Equity Research

                                AmerisourceBergen's (ABC) Q1 results are expected to gain on strength in pharmaceutical distribution segment.

                                  What's in Store for Pacific Biosciences (PACB) in Q4 Earnings?

                                  by Zacks Equity Research

                                  Pacific Biosciences (PACB) is likely to witness year-over-year decline in product revenues.

                                    What to Expect From Quest Diagnostics (DGX) in Q4 Earnings

                                    by Zacks Equity Research

                                    Quest Diagnostics (DGX) spots a slight turnaround of its sluggish revenue per requisition performance only in the last couple of quarters.

                                      Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

                                      by Zacks Equity Research

                                      Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

                                        Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?

                                        by Zacks Equity Research

                                        IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.

                                          Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

                                          by Zacks Equity Research

                                          Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

                                            Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

                                            by Zacks Equity Research

                                            Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

                                              Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?

                                              by Zacks Equity Research

                                              Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.

                                                Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

                                                by Zacks Equity Research

                                                Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.

                                                  Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.